Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate The Efficacy of The R-DA-EPOCH-21 And R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With De Novo Diffuse B-Cell Large Ce

Authors

  • Aminat Magomedova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Sergey Kravchenko National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Anna Misyurina National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Yana Mangasarova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Oleg Margolin National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Ekaterina Fastova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Fatima Babaeva National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Lilia Gorenkova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Madina Bagova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Ekaterina Nesterova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Ksenia Sychevskaya National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Tatyana Moiseeva National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Alla Kovrigina National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Tatyana Obukhova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Valentina Dvirnyk National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Salia Maryina National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Irina Galtseva National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Vladimir Galuzyak National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Karen Danishyan National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Irina Kostina National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Mikhail Gitis National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Andrey Sudarikov National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Elena Nikulina National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Bella Biderman National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Galina Klyasova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Gennady Galstyan National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Mikhail Spirin National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Sergey Kulikov National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Yulia Chabaeva National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Elena Zinina Regional Clinical Hospital, Hematology Department, Surgut, Russia
  • Irina Kryuchkova Research Institute of Fundamental Clinical Immunology, Hematology Department, Novosibirsk, Russia
  • Svetlana Sizikova Research Institute of Fundamental Clinical Immunology, Hematology Department, Novosibirsk, Russia
  • Vera Sergeyevicheva Research Institute of Fundamental Clinical Immunology, Hematology Department, Novosibirsk, Russia
  • Tatyana Ksenzova Regional Clinical Hospital No. 1, Hematology Department, Tyumen, Russia
  • Ekaterina Anikina Regional Clinical Hospital No. 1, Hematology Department, Tyumen, Russia
  • Tatyana Shelekhova Clinic of Occupational Pathology and Hematology, Hematology Department, Saratov, Russia
  • Olga Arzhanukhina Clinic of Occupational Pathology and Hematology, Hematology Department, Saratov, Russia
  • Kamil Kaplanov Regional Oncological Clinic No. 1, Hematology Department, Volgograd, Russia
  • Tatyana Konstantinova Regional Hematology Centre, Yekaterinburg, Russia
  • Olga Serdyuk Regional Oncological Clinic. Hematology Department, Krasnodar, Russia
  • Tatyana Sychyova Regional Clinical Hospital, Hematology Department, Astrakhan, Russia
  • Tatyana Chagorova Regional Oncological Clinic, Hematology Department, Penza, Russia
  • Irina Nec hunayeva City Hematology Centre, Novosibirsk, Russia
  • Lyudmila Anchukova Regional Clinical Hospital, Hematology Department, Vologda, Russia
  • Oksana Dzarasova Republican Clinical Hospital, Hematology Department, Vladikavkaz, Russia
  • Valery Savchenko National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)
  • Elena Parovichnikova National Medical Research Center for Hematology, Moscow, Russian Federation (Russia)

Abstract

Background: NHL-BFM-90 chemotherapy is highly effective in pediatric aggressive B-cell lymphomas.
Purpose: To evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DAEPOCH-21 programs
in adult patients with de novo DLBCL.
Patients and methods: Inclusion criteria: newly diagnosed DLBCL (NOS), no previous chemotherapy,
2 or more signs of poor prognosis, age 18-60. The protocol included 140 patients from 13 medical
centers in Russia: R-DA-EPOCH-21 – 33; R-DAEPOCH-21+auto-HSCT - 29; R-mNHL-BFM-90 - 33;
R-mNHL-BFM-90+ auto-HSCT -35 patients.
R-DA-EPOCH-21 branch: 6 courses were performed. If CR was not achieved, 2 courses of R-DHAP
were performed ± auto-HSCT. Branch R-mNHL-BFM-90 included 6 cycles: RA-RB-RA-RB-RA-RB.
If CR was not achieved, 2 courses of R-DHAP ± auto-HSCT.

Downloads

Published

2022-12-10

Issue

Section

Articles